214 related articles for article (PubMed ID: 37788996)
1. Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment.
Vaiana AM; Chen Y; Gelfond J; Johnson-Pais TL; Leach RJ; Ramamurthy C; Thompson IM; Morilak DA
Transl Psychiatry; 2023 Oct; 13(1):307. PubMed ID: 37788996
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer.
Sharp AM; Lertphinyowong S; Yee SS; Paredes D; Gelfond J; Johnson-Pais TL; Leach RJ; Liss M; Risinger AL; Sullivan AC; Thompson IM; Morilak DA
Psychopharmacology (Berl); 2019 Nov; 236(11):3183-3195. PubMed ID: 31139875
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine Reverses Impairment of Visuospatial Memory and Cognitive Flexibility Induced by Degarelix as a Model of Androgen Deprivation Therapy in Rats.
Vaiana AM; Asher AM; Tapia K; Morilak DA
Neuroendocrinology; 2024; 114(3):279-290. PubMed ID: 38104552
[TBL] [Abstract][Full Text] [Related]
4. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
[TBL] [Abstract][Full Text] [Related]
5. Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study.
Wu LM; Diefenbach MA; Gordon WA; Cantor JB; Cherrier MM
Urol Oncol; 2013 Nov; 31(8):1533-8. PubMed ID: 22975107
[TBL] [Abstract][Full Text] [Related]
6. Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study.
Wu LM; Tanenbaum ML; Dijkers MP; Amidi A; Hall SJ; Penedo FJ; Diefenbach MA
Soc Sci Med; 2016 May; 156():80-9. PubMed ID: 27019142
[TBL] [Abstract][Full Text] [Related]
7. Cognitive decline in prostate cancer patients undergoing ADT: a potential role for exercise training.
Mundell NL; Daly RM; Macpherson H; Fraser SF
Endocr Relat Cancer; 2017 Apr; 24(4):R145-R155. PubMed ID: 28209634
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function.
Reiss AB; Saeedullah U; Grossfeld DJ; Glass AD; Pinkhasov A; Katz AE
Clin Transl Oncol; 2022 May; 24(5):733-741. PubMed ID: 34743290
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.
Reiss AB; Gulkarov S; Pinkhasov A; Sheehan KM; Srivastava A; De Leon J; Katz AE
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256338
[TBL] [Abstract][Full Text] [Related]
10. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.
McGinty HL; Phillips KM; Jim HS; Cessna JM; Asvat Y; Cases MG; Small BJ; Jacobsen PB
Support Care Cancer; 2014 Aug; 22(8):2271-80. PubMed ID: 24859915
[TBL] [Abstract][Full Text] [Related]
11. Cognitive effects of long-term androgen deprivation therapy in older men with prostate cancer.
Pergolizzi D; Flaherty KR; Saracino RM; Root JC; Schofield E; Cassidy C; Katheria V; Patel SK; Dale W; Nelson CJ
Psychooncology; 2024 Mar; 33(3):e6336. PubMed ID: 38520472
[TBL] [Abstract][Full Text] [Related]
12. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
14. Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer.
Kluger J; Roy A; Chao HH
Curr Oncol Rep; 2020 Feb; 22(3):24. PubMed ID: 32048059
[TBL] [Abstract][Full Text] [Related]
15. A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2).
Crabb S; Morgan A; Hunter MS; Stefanopoulou E; Griffiths G; Richardson A; Fenlon D; Fleure L; Raftery J; Boxall C; Wilding S; Nuttall J; Eminton Z; Tilt E; O'Neill A; Bacon R; Martin J
Trials; 2023 Jul; 24(1):450. PubMed ID: 37430353
[TBL] [Abstract][Full Text] [Related]
16. Cognitive effects of hormone therapy in men with prostate cancer: a review.
Nelson CJ; Lee JS; Gamboa MC; Roth AJ
Cancer; 2008 Sep; 113(5):1097-106. PubMed ID: 18666210
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
18. Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.
Cherrier MM; Cross DJ; Higano CS; Minoshima S
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):394-402. PubMed ID: 29700388
[TBL] [Abstract][Full Text] [Related]
19. Effects of androgen deprivation on cerebral morphometry in prostate cancer patients--an exploratory study.
Chao HH; Hu S; Ide JS; Uchio E; Zhang S; Rose M; Concato J; Li CS
PLoS One; 2013; 8(8):e72032. PubMed ID: 23977199
[TBL] [Abstract][Full Text] [Related]
20. Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study.
Cherrier MM; Borghesani PR; Shelton AL; Higano CS
BMC Cancer; 2010 Jan; 10():1. PubMed ID: 20047689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
